Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a ...

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid ...

We report QoL outcomes in a prospective study to assess long-term outcomes in patients with WD treated with Trientine dihydrochloride (TETA-2HCl). Method Patients with WD who were withdrawn from ...